Next 10 |
home / stock / autl / autl articles
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 50 points on Friday. The Dow traded up 0.12% to 39,917...
Shares of Cracker Barrel Old Country Store, Inc. (NASDAQ:CBRL) fell sharply during Friday's session after the company reduced its dividend and...
U.S. stocks were mixed, with the Dow Jones gaining around 0.1% on Friday. Shares of Despegar.com, Corp. (NYSE:DESP) rose sharply during Friday'...
LONDON, May 13, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-gen...
LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-g...
LONDON, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-ge...
- Appointment of Elisabeth ("Lis") Leiderman, M.D. - Resignation of Kapil Dhingra, M.D. LONDON, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Autolus Th...
Pooled analysis of the FELIX Phase Ib/II study demonstrated prolonged event free survival and low overall immunotoxicity across all cohorts in r/...
In-person and webcast event on Sunday, 10 December, 2023 at 8:00 AM PT / 4:00 PM GMT Review of pooled analysis of the ongoing FELIX Phase Ib/II s...
News, Short Squeeze, Breakout and More Instantly...
Autolus Therapeutics plc Company Name:
AUTL Stock Symbol:
NASDAQ Market:
Autolus Therapeutics plc Website:
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention Ongoing CAR T persistence was associated wi...
Longer follow up and subset analyses from the pivotal FELIX Phase 2 data to be presented in oral presentations at ASCO and EHA Two patients enrolled in Phase 1 Systemic Lupus Erythematosus (SLE) trial; study on track for initial data end of 2024 Market Authorization Application (M...